Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry C Pitot

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium studySam J Lubner, Michelle R Mahoney, Jill L Kolesar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2005
A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancerGrace K Dy, Laura M Bruzek, Gary A Croghan, et al.
Cancer Chemotherapy and Pharmacology|December 6, 2005
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumorsHenry C Pitot, Alex A Adjei, Joel M Reid, et al.
Archives of Internal Medicine|September 30, 2010
Incidental findings in imaging research: evaluating incidence, benefit, and burdenNicholas M Orme, Joel G Fletcher, Hassan A Siddiki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancerAlex A Adjei, Grace K Dy, Charles Erlichman, et al.
Advances in Radiation Oncology|July 31, 2024
A Prospective Pilot Study of Pencil Beam Scanning Proton Radiation Therapy as a Component of Trimodality Therapy for Esophageal CancerChristopher L Hallemeier, Kenneth W Merrell, Michelle A Neben-Wittich, et al.
American Journal of Clinical Oncology|June 7, 2007
A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanomaSvetomir N Markovic, Vera J Suman, Ravi A Rao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancerAlex A Adjei, Gary A Croghan, Charles Erlichman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2007
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741Grace K Dy, James E Krook, Erin M Green, et al.
Oncotarget|February 11, 2017
Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer studyNilofer S Azad, Anthony El-Khoueiry, Jun Yin, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium studySam J Lubner, Michelle R Mahoney, Jill L Kolesar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2005
A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancerGrace K Dy, Laura M Bruzek, Gary A Croghan, et al.
Cancer Chemotherapy and Pharmacology|December 6, 2005
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumorsHenry C Pitot, Alex A Adjei, Joel M Reid, et al.
Archives of Internal Medicine|September 30, 2010
Incidental findings in imaging research: evaluating incidence, benefit, and burdenNicholas M Orme, Joel G Fletcher, Hassan A Siddiki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancerAlex A Adjei, Grace K Dy, Charles Erlichman, et al.
Advances in Radiation Oncology|July 31, 2024
A Prospective Pilot Study of Pencil Beam Scanning Proton Radiation Therapy as a Component of Trimodality Therapy for Esophageal CancerChristopher L Hallemeier, Kenneth W Merrell, Michelle A Neben-Wittich, et al.
American Journal of Clinical Oncology|June 7, 2007
A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanomaSvetomir N Markovic, Vera J Suman, Ravi A Rao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancerAlex A Adjei, Gary A Croghan, Charles Erlichman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2007
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741Grace K Dy, James E Krook, Erin M Green, et al.
Oncotarget|February 11, 2017
Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer studyNilofer S Azad, Anthony El-Khoueiry, Jun Yin, et al.
Pageof 9